



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 15 May 2023 (#17)

Confirm your intent to apply **ASAP**, but not later than **60 days** before the submission date.

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

To prepare an application can take **4-18 months**, depending on many factors:

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

Before starting your application, attend the **1) Generic Grant Writing Workshop** and then the **2) NIH Grant Writing Workshop**.

## Important Notices

**NOT-OD-23-109 Updates to Funding Opportunity Terminology.** Effective immediately, NIH will use the term **notice of funding opportunity (NOFO)** to refer to formal announcements of the availability of Federal funding through a financial assistance program. Previously, such announcements were referred to as funding opportunity announcements (**FOAs**).

**NOT-CA-23-067 Notice of Intent to Publish a Funding Opportunity Announcement for Translational Research Toward Development of a Kaposi Sarcoma Herpesvirus (KSHV) Vaccine (U01 Clinical Trial Optional).** The National Cancer Institute (NCI) intends to promote a new initiative by publishing a Notice of Funding Opportunity (NOFO) to solicit applications to expand the research scope and leverage the gains made through the “*Investigation of the Transmission of KSHV*” initiatives ([RFA-CA-18-013](#) and [RFA-CA-20-046](#)) to support basic and translational research that will guide the development of a prophylactic or therapeutic Kaposi sarcoma herpesvirus (KSHV) vaccine. A prophylactic KSHV vaccine could prevent primary KSHV infection, transmission, and subsequent development of KS and other KSHV-associated syndromes such as multicentric Castlemann disease (MCD), primary effusion lymphoma (PEL) and KSHV inflammatory cytokine syndrome (KICS) or ameliorate the severity of disease. A therapeutic KSHV vaccine could be helpful in preventing or treating KSHV disease in people who are already infected with KSHV. Approximately 3 to 4 awards each fiscal year of \$500,000 direct cost per year will be awarded. The presentation of this initiative to the NCI Board of Scientific Advisors (BSA) can be accessed at this link (at time frame 2:10): <https://videocast.nih.gov/watch=49366>.

## Parent Announcements

**NOT-OD-23-105 Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates  
Expiration Date: May 8, 2023 **Modified Key Dates Expiration Date: May 8, 2024**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)

- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

[NOT-AG-23-020](#) **Maximizing the Scientific Value of Secondary Analyses of Existing Cohorts and Datasets in Order to Address Research Gaps and Foster Additional Opportunities in Aging Research.** This Notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 08, 2024.

[NOT-AG-23-024](#) **Analyses of CALERIE Datasets and Biospecimens to Elucidate the Biological Effects and the Behavioral and Psychological Aspects of Sustained Caloric Restriction in Humans.** This notice applies to due dates on or after June 5, 2023 and subsequent receipt dates through May 8, 2024.

[NOT-OD-23-123](#) **Administrative Supplements to Enhance Institutional Data Science Capacity.** This NOSI invites applications for administrative supplements to eligible NIH awards to enhance data science capacity in institutions serving medically underserved communities and underrepresented students as described in the Notice of NIH's Interest in Diversity ([NOT-OD-20-031](#)). This NOSI aligns with the [NIH Data Science Strategic Plan](#) to ensure that data science advances in biomedical and health research can benefit all populations. To be eligible, the parent award must be able to receive funds in FY23 (October 1, 2022 to September 30, 2023) and must not be in the final year or a terminal no-cost extension period as of September 1, 2023. Supplement budget requests cannot exceed \$250,000/year in Direct Cost exclusive of Facilities and Administrative costs on sub-awards. Requests may be for up to two years of support, with second year support contingent upon satisfactory progress during the first year. Application Due Dates: June 19, 2023 and April 1, 2024, by 5:00 PM local time of applicant organization.

[NOT-TW-23-005](#) **Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research, Administrative Supplement Opportunity for South African International Research Training Grants (D43; U2R).** Scientific cooperation between the U.S. and the Republic of South Africa was initiated in 1995 and has grown in recent years. Recognizing that enhanced cooperative biomedical research would be of mutual benefit to the U.S. and South Africa, the NIH Director and the President of the South African Medical Research Council (MRC) signed a Memorandum of Understanding (MOU) in January 2013 to develop the U.S.-South Africa Program for Collaborative Biomedical Research. The first phase of this program included awards made in response to [RFA-AI-14-009](#), [RFA-AI-14-010](#), [RFA-AI-14-018](#), [RFA-AI-16-039](#), [RFA-AI-16-040](#), [RFA-AI-16-082](#), and [RFA-AI-16-083](#). The parent grant must have at least one year remaining as of the supplement application receipt date, exclusive of a no-cost extension, and the proposed project period cannot exceed that of the parent award. Supplement proposals must be within scope of the parent grant, that is proposed activities must be consistent with the specific aims of the parent award and must propose to train scientists from South African HDIs/South African Universities of Technology with limited resources or experience. Budgets up to \$150,000 total costs (direct plus F&A of 8%) for one year are allowed. Due date: June 23, 2023. Supplements will be awarded July 2023 -

[NOT-TW-23-006](#) **Administrative Supplements to Fogarty International Center's (FIC) Training Grants to Promote Diversity, Equity, and Inclusion (DEI).** Eligible parent grants are limited to D43 and U2R research training grants that have at least one year remaining at the time of submission, exclusive of no cost extensions. The contact PI of the parent grant must submit the application. Recipients in or working in South Africa should review the "related announcement" [NOT-TW-23-005](#) [Phase 2 of the U.S.-South Africa Program for Collaborative Biomedical Research: Administrative Supplement Opportunity for South African International Research Training Grants (D43; U2R)]. Only one application total may be submitted to either this or the companion opportunity. Budgets up to \$150,000 total costs (direct plus F&A of 8%) for one year are allowed with budget justification. Application Due Date: June 23, 2023 by 5:00 PM local time of applicant organization.

## Notice of Funding Opportunity (NOFO)

### 1. Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-180](#)

**Type:** R01

**Application Due Date:** December 07, 2023; December 07, 2024. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The objective of this Notice of Funding Opportunity (NOFO) is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs in cis and trans males and females of all ages. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies using drug development, and formulation science supported by animal model testing. Also supported are biobehavioral and behavioral/social studies to identify MPT user-desired rheological and biophysical factors (look, feel, effectiveness, safety, and duration of action) and other behavioral/social factors that could promote increased MPT adoption and use.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application.

### 2. Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-190](#)

**Type:** R

**Application Due Date:** December 20, 2023; December 20, 2024; December 22, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this NOFO is to solicit Research Project Grant (R01) applications for up to 3 years of support to develop and test interventions to reduce the impact of HIV-associated stigma on the prevention and treatment of HIV infection and/or AIDS, and on the quality of life of People Living with HIV and/or AIDS (PLWH). The NOFO will also support interventions to address the multiple intersecting stigmas and measurement of the stigmas at individual levels. Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

**Budget:** The combined budget for direct costs for the three-year project period may not exceed \$400,000. No more than \$200,000 in direct costs may be requested in any single year. The budget request must reflect the actual needs of the proposed project. Applicants may request a project period of up to three years.

### 3. HIV-associated Non-Communicable Diseases Research at Low- and Middle-Income Country Institutions (R21 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-191](#)

**Type:** R21

**Application Due Date:** December 08, 2023; December 09, 2024; December 08, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The goals of this program are to support locally relevant research in critical areas of HIV-associated non-communicable diseases (NCDs) at Low- and Middle-Income Country (LMIC) Institutions, to enhance research capacity, and to build a network of researchers both within and across LMICs to address this critical burden. This initiative is expected to stimulate new research on the interplay between HIV and development of NCDs in persons living with HIV (PLWH). This includes exploratory studies to uncover the extent to which HIV infection influences the etiopathogenesis of the NCDs; and to identify and develop appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for PLWH with the comorbid conditions. Research teams should contain an appropriate mix of expertise to accomplish the proposed studies, including partnerships between HIV and NCD researchers who can initiate new ideas, and determine feasibility of novel approaches to understand and reduce the long-term suffering from the comorbid disorders. Applicants will also be asked to address the needs of collaborating LMIC institutions to develop capacity for carrying out research in this field. Applicants should develop their studies in keeping with the NIH HIV/AIDS Research Priorities

- <https://www.oar.nih.gov/hiv-policy-and-research/research-priorities>;
- <https://grants.nih.gov/grants/guide/notice-files/NOT-OD-20-018.html>.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$150,000 may be requested in any single year. The budget request must reflect the actual needs of the proposed project.

#### 4. HIV Prevention and Alcohol (R34 Clinical Trials Optional)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink:** [PAS-23-172](#)

**Type: R34**

**Application Due Date: September 07, 2023 through to May 07, 2026** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The NOFO seeks to expand the HIV/AIDS prevention toolkit among alcohol impacted populations with a range of patterns of episodic and long-term use and associated behavioral and biological risks for HIV acquisition. This includes integration of effective prevention and treatment interventions with an understanding of the overarching framework for reducing the incidence of new infections by facilitating cross-cutting informative research.

This R34 Notice of Funding Opportunity (NOFO) supports studies that are both necessary and sufficient to inform the planning of a clinical trial within the scope of the companion announcement RFA- AA-21-016 HIV Prevention and Alcohol (R01 Clinical Trials Optional). The NIAAA expects that applications to this NOFO will describe the planned clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent trial. Furthermore, this NOFO will support research projects that are designed to provide results that will be sufficient to inform the future trial without further studies. The planned Phase II, III, or IV trial must be primarily intended to test the efficacy, safety, clinical management, or implementation of intervention(s) in the prevention of HIV. In this NIAAA funding opportunity for pilot clinical trials the R34 mechanism is intended to provide new information that answers a scientific or operational question(s) which may be pragmatic in nature and, therefore, informs the final development of a clinical trial and testing of intervention tools.

**Budget:** NIH intends to fund an estimate of 2 - 4 awards, corresponding to a total of \$1,500,000, for fiscal year 2024 . Future year amounts will depend on annual appropriations. The budget during the three-year project period may not exceed \$450,000 direct cost, with no more than \$225,000 direct cost requested in a single year. The project period is limited to 3 years.

#### 5. BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink:** [RFA-MH-23-290](#)

**Type: R01**

**Application Due Date: June 07, 2023** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is to encourage research that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

#### 6. BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink:**

**Type: UG3/UH3**

**Application Due Date: June 07, 2023; June 07, 2024.** Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative notice of funding opportunity is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits in large brains. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell- and circuit-specific tools will require extensive focused research designed to remove barriers for targeted circuit manipulation. In addition to identification and removal of barriers, the need to delineate dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cell- and circuit-specific mapping, monitoring, and manipulating tools has been developed for use in model organisms, primarily rodents, fish and flies. These cutting-edge tools are increasingly adaptable to larger mammalian brains and, more importantly, are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains or those that are more directly relevant to the human brain is the focus of this initiative. The initiative will support initial proof of principle studies aimed at demonstrating the feasibility of using the cutting-edge approaches in humans and other mammalian species (e.g., non-human primate [NHP]/sheep/pigs).

**Budget:** Issuing IC and partner [components](#) intend to commit an estimated total of \$10,000,000 to fund 6-9 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The duration of the UG3 phase cannot exceed 3 years and the total duration of the UG3/UH3 phases combined may not exceed 5 years.

Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: [Christa](#)  
[e: cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: [Lizél](#)  
[e: lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105